Patent Grant
7146217
Several embodiments of methods and apparatus in accordance with the invention are related to electrically stimulating a region in the cortex or other area of the brain to bring about a lasting change in a physiological function and/or a mental process of a patient.
A wide variety of mental and physical processes are known to be controlled or are influenced by neural activity in particular regions of the brain. In some areas of the brain, such as in the sensory or motor cortices, the organization of the brain resembles a map of the human body; this is referred to as the “somatotopic organization of the brain.” There are several other areas of the brain that appear to have distinct functions that are located in specific regions of the brain in most individuals. For example, areas of the occipital lobes relate to vision, regions of the left inferior frontal lobes relate to language in the majority of people, and regions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect. This type of location-specific functional organization of the brain, in which discrete locations of the brain are statistically likely to control particular mental or physical functions in normal individuals, is herein referred to as the “functional organization of the brain.”
Many problems or abnormalities with body functions can be caused by damage, disease and/or disorders of the brain. A stroke, for example, is one very common condition that damages the brain. Strokes are generally caused by emboli (e.g., obstruction of a vessel), hemorrhages (e.g., rupture of a vessel), or thrombi (e.g., clotting) in the vascular system of a specific region of the cortex, which in turn generally causes a loss or impairment of a neural function (e.g., neural functions related to face muscles, limbs, speech, etc.). Stroke patients are typically treated using physical therapy to rehabilitate the loss of function of a limb or another affected body part. For most patients, little can be done to improve the function of the affected limb beyond the recovery that occurs naturally without intervention. One existing physical therapy technique for treating stroke patients constrains or restrains the use of a working body part of the patient to force the patient to use the affected body part. For example, the loss of use of a limb is treated by restraining the other limb. Although this type of physical therapy has shown some experimental efficacy, it is expensive, time-consuming and little-used. Stroke patients can also be treated using physical therapy plus adjunctive therapies. For example, some types of drugs, such as amphetamines, that increase the activation of neurons in general, appear to enhance neural networks; these drugs, however, have limited efficacy because they are very non-selective in their mechanisms of action and cannot be delivered in high concentrations directly at the site where they are needed. Therefore, there is a need to develop effective treatments for rehabilitating stroke patients and patients that have other types of brain damage.
Other brain disorders and diseases are also difficult to treat. Alzheimer's disease, for example, is known to affect portions of the cortex, but the cause of Alzheimer's disease and how it alters the neural activity in the cortex is not fully understood. Similarly, the neural activity of brain disorders (e.g., depression and obsessive-compulsive behavior) is also not fully understood. Therefore, there is also a need to develop more effective treatments for other brain disorders and diseases.
The neural activity in the brain can be influenced by electrical energy that is supplied from an external source outside of the body. Various neural functions can thus be promoted or disrupted by applying an electrical current to the cortex or other region of the brain. As a result, the quest for treating damage, disease and disorders in the brain have led to research directed toward using electricity or magnetism to control brain functions.
One type of treatment is transcranial electrical stimulation (TES), which involves placing an electrode on the exterior of the scalp and delivering an electrical current to the brain through the scalp and skull. Patents directed to TES include: U.S. Pat. No. 5,540,736 issued to Haimovich et al. (for providing analgesia); U.S. Pat. No. 4,140,133 issued to Katrubin et al. (for providing anesthesia); U.S. Pat. No. 4,646,744 issued to Capel (for treating drug addiction, appetite disorders, stress, insomnia and pain); and U.S. Pat. No. 4,844,075 issued to Liss et al. (for treating pain and motor dysfunction associated with cerebral palsy). TES, however, is not widely used because the patients experience a great amount of pain and the electrical field is difficult to direct or focus accurately.
Another type of treatment is transcranial magnetic stimulation (TMS), which involves producing a high-powered magnetic field adjacent to the exterior of the scalp over an area of the cortex. TMS does not cause the painful side effects of TES. Since 1985, TMS has been used primarily for research purposes in brain-mapping endeavors. Recently, however, potential therapeutic applications have been proposed primarily for the treatment of depression. A small number of clinical trials have found TMS to be effective in treating depression when used to stimulate the left prefrontal cortex.
The TMS treatment of a few other patient groups have been studied with promising results, such as patients with Parkinson's disease and hereditary spinocerebellar degeneration. Patents and published patent applications directed to TMS include: published international patent application WO 98/06342 (describing a transcranial magnetic stimulator and its use in brain mapping studies and in treating depression); U.S. Pat. No. 5,885,976 issued to Sandyk (describing the use of transcranial magnetic stimulation to treat a variety of disorders allegedly related to deficient serotonin neurotransmission and impaired pineal melatonin functions); and U.S. Pat. No. 5,092,835 issued to Schurig et al. (describing the treatment of neurological disorders (such as autism), treatment of learning disabilities, and augmentation of mental and physical abilities of “normal” people by a combination of transcranial magnetic stimulation and peripheral electrical stimulation).
Independent studies have also demonstrated that TMS is able to produce a lasting change in neural activity within the cortex that occurs for a period of time after terminating the TMS treatment (“neuroplasticity”). For example, Ziemann et al., Modulation of Plasticity in Human Motor Cortex after Forearm Ischemic Nerve Block, 18 J Neuroscience 1115 (February 1998), disclose that TMS at subthreshold levels (e.g., levels at which movement was not induced) in neuro-block models that mimic amputation was able to modify the lasting changes in neural activity that normally accompany amputation. Similarly, Pascual-Leone et al. (submitted for publication) disclose that applying TMS over the contralateral motor cortex in normal subjects who underwent immobilization of a hand in a cast for 5 days can prevent the decreased motor cortex excitability normally associated with immobilization. Other researchers have proposed that the ability of TMS to produce desired changes in the cortex may someday be harnessed to enhance neuro-rehabilitation after a brain injury, such as stroke, but there are no published studies to date.
Other publications related to TMS include Cohen et al., Studies of Neuroplasticity With Transcranial Magnetic Stimulation, 15 J. Clin. Neurophysiol. 305 (1998); Pascual-Leone et al., Transcranial Magnetic Stimulation and Neuroplasticity, 37 Neuropsychologia 207 (1999); Stefan et al., Induction of Plasticity in the Human Motor Cortex by Paired Associative Stimulation, 123 Brain 572 (2000); Sievner et al., Lasting Cortical Activation after repetitive TMS of the Motor Cortex, 54 Neurology 956 (February 2000); Pascual-Leone et al., Study and Modulation of Human Cortical Excitability With Transcranial Magnetic Stimulation, 15 J. Clin. Neurophysiol. 333 (1998); and Boylan et al., Magnetoelectric Brain Stimulation in the Assessment Of Brain Physiology And Pathophysiology, 111 Clin. Neurophysiology 504 (2000).
Although TMS appears to be able to produce a change in the underlying cortex beyond the time of actual stimulation, TMS is not presently effective for treating many patients because the existing delivery systems are not practical for applying stimulation over an adequate period of time. TMS systems, for example, are relatively complex and require stimulation treatments to be performed by a healthcare professional in a hospital or physician's office. TMS systems also may not be reliable for longer-term therapies because it is difficult to (a) accurately localize the region of stimulation in a reproducible manner, and (b) hold the device in the correct position over the cranium for a long period, especially when a patient moves or during rehabilitation. Furthermore, current TMS systems generally do not sufficiently focus the electromagnetic energy on the desired region of the cortex for many applications. As such, the potential therapeutic benefit of TMS using existing equipment is relatively limited.
Direct and indirect electrical stimulation of the central nervous system has also been proposed to treat a variety of disorders and conditions. For example, U.S. Pat. No. 5,938,688 issued to Schiff notes that the phenomenon of neuroplasticity may be harnessed and enhanced to treat cognitive disorders related to brain injuries caused by trauma or stroke. Schiff's implant is designed to increase the level of arousal of a comatose patient by stimulating deep brain centers involved in consciousness. To do this, Schiffs invention involves electrically stimulating at least a portion of the patient's intralaminar nuclei (i.e., the deep brain) using, e.g., an implantable multipolar electrode and either an implantable pulse generator or an external radiofrequency controlled pulse generator. Schiff's deep brain implant is highly invasive, however, and could involve serious complications for the patient.
Likewise, U.S. Pat. No. 6,066,163 issued to John acknowledges the ability of the brain to overcome some of the results of an injury through neuroplasticity. John also cites a series of articles as evidence that direct electrical stimulation of the brain can reverse the effects of a traumatic injury or stroke on the level of consciousness. The system disclosed in John stimulates the patient and modifies the parameters of stimulation based upon the outcome of comparing the patient's present state with a reference state in an effort to optimize the results. Like Schiff, however, the invention disclosed in John is directed to a highly invasive deep brain stimulation system.
Another device for stimulating a region of the brain is disclosed by King in U.S. Pat. No. 5,713,922. King discloses a device for cortical surface stimulation having electrodes mounted on a paddle implanted under the skull of the patient. The electrodes are implanted on the surface of the brain in a fixed position. The electrodes in King accordingly cannot move to accommodate changes in the shape of the brain. King also discloses that the electrical pulses are generated by a pulse generator that is implanted in the patient remotely from the cranium (e.g., subclavicular implantation). The pulse generator is not directly connected to the electrodes, but rather it is electrically coupled to the electrodes by a cable that extends from the remotely implanted pulse generator to the electrodes implanted in the cranium. The cable disclosed in King extends from the paddle, around the skull, and down the neck to the subclavicular location of the pulse generator.
King discloses implanting the electrodes in contact with the surface of the cortex to create paresthesia, which is a sensation of vibration or “buzzing” in a patient. More specifically, King discloses inducing paresthesia in large areas by applying electrical stimulation to a higher element of the central nervous system (e.g., the cortex). As such, King discloses placing the electrodes against particular regions of the brain to induce the desired paresthesia. The purpose of creating paresthesia over a body region is to create a distracting stimulus that effectively reduces perception of pain in the body region. Thus, King appears to require stimulation above activation levels.
Although King discloses a device that stimulates a region on the cortical surface, this device is expected to have several drawbacks. First, it is expensive and time-consuming to implant the pulse generator and the cable in the patient. Second, it appears that the electrodes are held at a fixed elevation that does not compensate for anatomical changes in the shape of the brain relative to the skull, which makes it difficult to accurately apply an electrical stimulation to a desired target site of the cortex in a focused, specific manner. Third, King discloses directly activating the neurons to cause paresthesia, which is not expected to cause entrainment of the activity in the stimulated population of neurons with other forms of therapy or adaptive behavior, such as physical or occupational therapy. Thus, King is expected to have several drawbacks.
King and the other foregoing references are also expected to have drawbacks in producing the desired neural activity because these references generally apply the therapy to the region of the brain that is responsible for the physiological function or mental process according to the functional organization of the brain. In the case of a brain injury or disease, however, the region of the brain associated with the affected physiological function or cognitive process may not respond to stimulation therapies. Thus, existing techniques may not produce adequate results that last beyond the stimulation period.
The following disclosure describes several methods and apparatus for intracranial electrical stimulation to treat or otherwise effectuate a change in neural-functions of a patient. Several embodiments of methods in accordance with the invention are directed toward enhancing or otherwise inducing neuroplasticity to effectuate a particular neural-function. Neuroplasticity refers to the ability of the brain to change or adapt over time. It was once thought adult brains became relatively “hard wired” such that functionally significant neural networks could not change significantly over time or in response to injury. It has become increasingly more apparent that these neural networks can change and adapt over time so that meaningful function can be regained in response to brain injury. An aspect of several embodiments of methods in accordance with the invention is to provide the appropriate triggers for adaptive neuroplasticity. These appropriate triggers appear to cause or enable increased synchrony of functionally significant populations of neurons in a network.
Electrically enhanced or induced neural stimulation in accordance with several embodiments of the invention excites a portion of a neural network involved in a functionally significant task such that a selected population of neurons can become more strongly associated with that network. Because such a network will subserve a functionally meaningful task, such as motor relearning, the changes are more likely to be lasting because they are continually being reinforced by natural use mechanisms. The nature of stimulation in accordance with several embodiments of the invention ensures that the stimulated population of neurons links to other neurons in the functional network. It is expected that this occurs because action potentials are not actually caused by the stimulation, but rather are caused by interactions with other neurons in the network. Several aspects of the electrical stimulation in accordance with selected embodiments of the invention simply allows this to happen with an increased probability when the network is activated by favorable activities, such as rehabilitation or limb use.
The methods in accordance with the invention can be used to treat brain damage (e.g., stroke, trauma, etc.), brain disease (e.g., Alzheimer's, Pick's, Parkinson's, etc.), and/or brain disorders (e.g., epilepsy, depression, etc.). The methods in accordance with the invention can also be used to enhance functions of normal, healthy brains (e.g., learning, memory, etc.), or to control sensory functions (e.g., pain).
Certain embodiments of methods in accordance with the invention electrically stimulate the brain at a stimulation site where neuroplasticity is occurring. The stimulation site may be different than the region in the brain where neural activity is typically present to perform the particular function according to the functional organization of the brain. In one embodiment in which neuroplasticity related to the neural-function occurs in the brain, the method can include identifying the location where such neuroplasticity is present. This particular procedure may accordingly enhance a change in the neural activity to assist the brain in performing the particular neural function. In an alternative embodiment in which neuroplasticity is not occurring in the brain or is not detected using imaging techniques, an aspect is to induce neuroplasticity at a stimulation site where it is expected to occur. This particular procedure may thus induce a change in the neural activity to instigate performance of the neural function. Several embodiments of these methods are expected to produce the intended neural activity at the stimulation site.
The specific details of certain embodiments of the invention are set forth in the following description and in
A. Methods for Electrically Stimulating Regions of the Brain
1. Embodiments of Electrically Enhancing Neural Activity
The method 100 includes a diagnostic procedure 102 involving identifying a stimulation site at a location of the brain where an intended neural activity related to the neural-function is present. In one embodiment, the diagnostic procedure 102 includes generating the intended neural activity in the brain from a “peripheral” location that is remote from the normal location, and then determining where the intended neural activity is actually present in the brain. In an alternative embodiment, the diagnostic procedure 102 can be performed by identifying a stimulation site where neural activity has changed in response to a change in the neural-function. The method 100 continues with an implanting procedure 104 involving positioning first and second electrodes at the identified stimulation site, and a stimulating procedure 106 involving applying an electrical current between the first and second electrodes. Many embodiments of the implanting procedure 104 position two or more electrodes at the stimulation site, but other embodiments of the implanting procedure involve positioning only one electrode at the stimulation site and another electrode remotely from the stimulation site. As such, the implanting procedure 104 of the method 100 can include implanting at least one electrode at the stimulation site. The procedures 102–106 are described in greater detail below.
The neural activity in the first region 210, however, can be impaired. In a typical application, the diagnostic procedure 102 begins by taking an image of the brain 200 that is capable of detecting neural activity to determine whether the intended neural activity associated with the particular neural function of interest is occurring at the region of the brain 200 where it normally occurs according to the functional organization of the brain.
One embodiment of the diagnostic procedure 102 involves generating the intended neural activity remotely from the first region 210 of the brain, and then detecting or sensing the location in the brain where the intended neural activity has been generated. The intended neural activity can be generated by applying an input that causes a signal to be sent to the brain. For example, in the case of a patient that has lost the use of a limb, the affected limb is moved and/or stimulated while the brain is scanned using a known imaging technique that can detect neural activity (e.g., functional MRI, positron emission tomography, etc.). In one specific embodiment, the affected limb can be moved by a practitioner or the patient, stimulated by sensory tests (e.g., pricking), or subject to peripheral electrical stimulation. The movement/stimulation of the affected limb produces a peripheral neural signal from the limb that is expected to generate a response neural activity in the brain. The location in the brain where this response neural activity is present can be identified using the imaging technique.
An alternative embodiment of the diagnostic procedure 102 involves identifying a stimulation site at a second location of the brain where the neural activity has changed in response to a change in the neural-function of the patient. This embodiment of the method does not necessarily require that the intended neural activity be generated by peripherally actuating or stimulating a body part. For example, the brain can be scanned for neural activity associated with the impaired neural-function as a patient regains use of an affected limb or learns a task over a period of time. This embodiment, however, can also include peripherally generating the intended neural activity remotely from the brain explained above.
In still another embodiment, the diagnostic procedure 102 involves identifying a stimulation site at a location of the brain where the intended neural activity is developing to perform the neural-function. This embodiment is similar to the other embodiments of the diagnostic procedure 102, but it can be used to identify a stimulation site at (a) the normal region of the brain where the intended neural activity is expected to occur according to the functional organization of the brain and/or (b) a different region where the neural activity occurs because the brain is recruiting additional matter to perform the neural-function. This particular embodiment of the method involves monitoring neural activity at one or more locations where the neural activity occurs in response to the particular neural-function of interest. For example, to enhance the ability to learn a particular task (e.g., playing a musical instrument, memorizing, etc.), the neural activity can be monitored while a person performs the task or thinks about performing the task. The stimulation sites can be defined by the areas of the brain where the neural activity has the highest intensity, the greatest increases, and/or other parameters that indicate areas of the brain that are being used to perform the particular task.
Several embodiments of methods for enhancing neural activity in accordance with the invention are expected to provide results that create, promote or prolong the desired neural-function even after terminating the stimulation. Before the present invention, electrical and magnetic stimulation techniques typically stimulated the normal locations of the brain where neural activity related to the neural-functions occurred according to the functional organization of the brain. Such conventional techniques, however, may not be effective because the neurons in the “normal locations” of the brain may not be capable of carrying out the neural activity because of brain damage, disease, disorder, and/or because of variations of the location specific to individual patients. Several embodiments of methods for enhancing neural activity in accordance with the invention overcome this drawback by identifying a stimulation site based on neuroplastic activity that appears to be related to the neural-function. Several other embodiments of the invention create, promote, or prolong neuroplastic activity by selecting a stimulation site based on a specific anatomic location where neuroplasticity is suspected of occurring or is expected to occur to carry out a particular function. By first identifying or selecting a location in the brain that is being recruited or is suspected of being recruited to perform the neural activity, it is expected that therapies (e.g., electrical, magnetic, genetic, biologic, and/or pharmaceutical) applied to this location will be more effective than conventional techniques. This is because the location that the brain is recruiting for the neural activity may not be the “normal location” where the neural activity would normally occur according to the functional organization of the brain. Therefore, several embodiments of methods for enhancing neural activity in accordance with the invention are expected to provide results that last for a period of time after terminating the stimulation because the therapies are applied to the portion of the brain where neural activity for carrying out the neural-function actually occurs in the particular patient.
2. Electrically Inducing Desired Neural Activity
The method 100 for effectuating a neural-function can also be used to induce neural activity in a region of the brain where such neural activity is not present. As opposed to the embodiments of the method 100 described above for enhancing existing neural activity, the embodiments of the method 100 for inducing neural activity initiate the neural activity at a stimulation site where neuroplasticity is expected to occur. In this particular situation, an image of the brain seeking to locate neuroplasticity may be similar to
A stimulation site may be identified by estimating where the brain will likely recruit neurons for performing the neural-function. In one embodiment, the location of the stimulation site is estimated by defining a region of the brain that is proximate to the normal location where neural activity related to the neural-function is generally present according to the functional organization of the brain. An alternative embodiment for locating the stimulation site includes determining where neuroplasticity has typically occurred in patients with similar symptoms. For example, if the brain typically recruits a second region of the cortex to compensate for a loss of neural activity in the normal region of the cortex, then the second region of the cortex can be selected as the stimulation site either with or without imaging the neural activity in the brain.
Several embodiments of methods for inducing neural activity in accordance with the invention are also expected to provide lasting results that initiate and promote a desired neural-function. By first estimating the location of a stimulation site where desired neuroplasticity is expected to occur, therapies applied to this location may be more effective than conventional therapies for reasons that are similar to those explained above regarding enhancing neural activity. Additionally, methods for inducing neural activity may be easier and less expensive to implement because they do not require generating neural activity and/or imaging the brain to determine where the intended neural activity is occurring before applying the therapy.
3. Inducing or Enhancing Neuroplasticity Based on Specific Anatomic Locations
Another aspect of the present invention is to induce or enhance neuroplasticity at specific anatomic locations for carrying out particular functions. Many of the foregoing methods described above determine the stimulation site by imaging the brain to locate regions where neuroplasticity is occurring, but it may also be desirable to select the stimulation site according to a specific anatomic location either with or without imaging. Accordingly, several additional embodiments of methods in accordance with the invention define a specific anatomic region for inducing or enhancing neuroplasticity to carry out a desired function.
The embodiment of the method 100a described above can be used even without directly testing for the presence of neuroplasticity using functional MRI or other imaging techniques. This particular method is premised upon the finding that regions of neuroplasticity associated with carrying out specific functions can be expected to occur at particular anatomic locations in the brain. For example, specific regions of the cortex are likely to be sites where neuroplasticity occurs in response to particular types of brain damage or disorders. A region of neuroplasticity in the brain can be a location that is suspected or proven to be undergoing a sequence of biochemical, electrophysiological, structural, and cellular changes that produce a lasting change in neural-activity for carrying out a mental or physical function. The lasting change may be any period after terminating the activating procedure 116a, such as a few seconds or as long as the life of the patient. The selecting procedure 112a is unique in that it specifically targets a particular anatomic location as a region of neuroplasticity for carrying out a specific function.
The selecting procedure 112a can be performed by providing a first listing containing a plurality of physical and/or cognitive conditions, and a second listing containing a plurality of neural-sites in the cortex where neural-activity is suspected to change for carrying out particular functions. In this embodiment, the stimulation site can be selected by identifying a physical and/or cognitive condition in the first listing that correlates to a condition of the patient, and then determining a corresponding neural-site in the cortex of the patient using the second listing. This embodiment of the selecting procedure 112a is expected to be particularly useful for treating specific conditions that involve particular types of brain damage or disorders.
It will be appreciated that the foregoing specific embodiments of the method 100a provide a few examples of the particular anatomic locations where the electrodes may be positioned. The method 100a is not limited to the foregoing embodiments, but rather other anatomical locations can be stimulated for treating other conditions in accordance with this method. For example, the selecting procedure 112a can alternatively be performed by choosing a stimulation site adjacent to a damaged region of the cortex where neural-activity for carrying out the altered function was performed before the cortex was damaged.
4. Applications of Methods for Electrically Stimulating Regions of the Brain
The foregoing methods for enhancing existing neural activity or inducing new neural activity are expected to be useful for many applications. As explained above, several embodiments of the method 100 involve determining an efficacious location of the brain to enhance or induce an intended neural activity that causes the desired neural-functions to occur. Additional therapies can also be implemented in combination with the electrical stimulation methods described above. Several specific applications using embodiments of electrical stimulation methods in accordance with the invention either alone or with adjunctive therapies will now be described, but it will be appreciated that the methods in accordance with the invention can be used in many additional applications.
The embodiments of the electrical stimulation methods described above are expected to be particularly useful for rehabilitating a loss of mental functions, motor functions and/or sensory functions caused by damage to the brain. In a typical application, the brain has been damaged by a stroke or trauma (e.g., automobile accident). The extent of the particular brain damage can be assessed using functional MRI or another appropriate imaging techniques as explained above with respect to
Several specific applications are expected to have a stimulation site in the cortex because neural activity in this part of the brain effectuates motor functions and/or sensory functions that are typically affected by a stroke or trauma. In these applications, the electrical stimulation can be applied directly to the pial surface of the brain or at least proximate to the pial surface (e.g., the dura mater, the fluid surrounding the cortex, or neurons within the cortex). Suitable devices for applying the electrical stimulation to the cortex are described in detail with reference to
The electrical stimulation methods can also be used with adjunctive therapies to rehabilitate damaged portions of the brain. In one embodiment, the electrical stimulation methods can be combined with physical therapy and/or drug therapies to rehabilitate an affected neural function. For example, if a stroke patient has lost the use of a limb, the patient can be treated by applying the electrical therapy to a stimulation site where the intended neural activity is present while the affected limb is also subject to physical therapy. An alternative embodiment can involve applying the electrical therapy to the stimulation site and chemically treating the patient using amphetamines or other suitable drugs.
The embodiments of the electrical stimulation methods described above are also expected to be useful for treating brain diseases, such as Alzheimer's, Parkinson's, and other brain diseases. In this application, the stimulation site can be identified by monitoring the neural activity using functional MRI or other suitable imaging techniques over a period of time to determine where the brain is recruiting material to perform the neural activity that is being affected by the disease. It may also be possible to identify the stimulation site by having the patient try to perform an act that the particular disease has affected, and monitoring the brain to determine whether any response neural activity is present in the brain. After identifying where the brain is recruiting additional matter, the electrical stimulation can be applied to this portion of the brain. It is expected that electrically stimulating the regions of the brain that have been recruited to perform the neural activity which was affected by the disease will assist the brain in offsetting the damage caused by the disease.
The embodiments of the electrical stimulation methods described above are also expected to be useful for treating neurological disorders, such as depression, passive-aggressive behavior, weight control, and other disorders. In these applications, the electrical stimulation can be applied to a stimulation site in the cortex or another suitable part of the brain where neural activity related to the particular disorder is present. The embodiments of electrical stimulation methods for carrying out the particular therapy can be adapted to either increase or decrease the particular neural activity in a manner that produces the desired results. For example, an amputee may feel phantom sensations associated with the amputated limb. This phenomenon can be treated by applying an electrical pulse that reduces the phantom sensations. The electrical therapy can be applied so that it will modulate the ability of the neurons in that portion of the brain to execute sensory functions.
The electrical stimulation methods in accordance with the invention can use several different pulse forms to effectuate the desired neuroplasticity. The pulses can be a bi-phasic or monophasic stimulus that is applied to achieve a desired potential in a sufficient percentage of a population of neurons at the stimulation site. In one embodiment, the pulse form has a frequency of approximately 2–1000 Hz, but the frequency may be particularly useful in the range of approximately 40–200 Hz. For example, initial clinical trials are expected to use a frequency of approximately 50–100 Hz. The pulses can also have pulse widths of approximately 10 μs–100 ms, or more specifically the pulse width can be approximately 20–200 μs. For example, a pulse width of 50–100 μs may produce beneficial results.
It is expected that one particularly useful application of the invention involves enhancing or inducing neuroplasticity by raising the resting membrane potential of neurons to bring the neurons closer to the threshold level for firing an action potential. Because the stimulation raises the resting membrane potential of the neurons, it is expected that these neurons are more likely to “fire” an action potential in response to excitatory input at a lower level.
The actual electrical potential applied to electrodes implanted in the brain to achieve a subthreshold potential stimulation will vary according to the individual patient, the type of therapy, the type of electrodes, and other factors. In general, the pulse form of the electrical stimulation (e.g., the frequency, pulse width, wave form, and voltage potential) is selected to raise the resting potential in a sufficient number neurons at the stimulation site to a level that is less than a threshold potential for a statistical portion of the neurons in the population. The pulse form, for example, can be selected so that the applied voltage of the stimulus achieves a change in the resting potential of approximately 10%–95%, and more specifically of 60%–80%, of the difference between the unstimulated resting potential and the threshold potential.
In one specific example of a subthreshold application for treating a patient's hand, electrical stimulation is not initially applied to the stimulation site. Although physical therapy related to the patient's hand may cause some activation of a particular population of neurons that is known to be involved in “hand function,” only a low level of activation might occur because physical therapy only produces a low level of action potential generation in that population of neurons. However, when the subthreshold electrical stimulation is applied, the resting membrane potentials of the neurons in the stimulated population are elevated. These neurons now are much closer to the threshold for action potential formation such that when the same type of physical therapy is given, this population of cells will have a higher level of activation because these cells are more likely to fire action potentials.
Subthreshold stimulation may produce better results than simply stimulating the neurons with sufficient energy levels to exceed the threshold for action potential formation. One aspect of subthreshold stimulation is to increase the probability that action potentials will occur in response to the ordinary causes of activation—such as physical therapy. This will allow the neurons in this functional network to become entrained together, or “learn” to become associated with these types of activities. If neurons are given so much electricity that they continually fire action potentials without additional excitatory inputs (suprathreshold stimulation), this will create “noise” and disorganization that will not likely cause improvement in function. In fact, neurons that are “overdriven” soon deplete their neurotransmitters and effectively become silent.
The application of a subthreshold stimulation is very different than suprathreshold stimulation. Subthreshold stimulation in accordance with several embodiments of the invention, for example, does not intend to directly make neurons fire action potentials with the electrical stimulation in a significant population of neurons at the stimulation site. Instead, subthreshold stimulation attempts to decrease the “activation energy” required to activate a large portion of the neurons at the stimulation site. As such, subthreshold stimulation in accordance with certain embodiments of the invention is expected to increase the probability that the neurons will fire in response to the usual intrinsic triggers, such as trying to move a limb, physical therapy, or simply thinking about movement of a limb, etc. Moreover, coincident stimulation associated with physical therapy is expected to increase the probability that the action potentials that are occurring with an increased probability due to the subthreshold stimulation will be related to meaningful triggers, and not just “noise.”
The stimulus parameters set forth above, such as a frequency selection of approximately 50–100 Hz and an amplitude sufficient to achieve an increase of 60% to 80% of the difference between the resting potential and the threshold potential are specifically selected so that they will increase the resting membrane potential of the neurons, thereby increasing the likelihood that they will fire action potentials, without directly causing action potentials in most of the neuron population. In addition, and as explained in more detail below with respect to
B. Devices for Electrically Stimulating Regions of the Brain
1. Implantable Stimulation Apparatus with Integrated Pulse Systems
The embodiment of the stimulation apparatus 600 shown in
Several embodiments of the stimulation apparatus 600 are expected to be more effective than existing transcranial electrical stimulation devices and transcranial magnetic stimulation devices. It will be appreciated that much of the power required for transcranial therapies is dissipated in the scalp and skull before it reaches the brain. In contrast to conventional transcranial stimulation devices, the stimulation apparatus 600 is implanted so that the electrodes are at least proximate to the pial surface of the brain 708. Several embodiments of methods in accordance with the invention can use the stimulation apparatus 600 to apply an electrical therapy directly to the pia mater 708, the dura mater 706, and/or another portion of the cortex 709 at significantly lower power levels than existing transcranial therapies. For example, a potential of approximately 1 mV to 10 V can be applied to the electrodes 660; in many instances a potential of 100 mV to 5 V can be applied to the electrodes 660 for selected applications. It will also be appreciated that other potentials can be applied to the electrodes 660 of the stimulation apparatus 600 in accordance with other embodiments of the invention.
Selected embodiments of the stimulation apparatus 600 are also capable of applying stimulation to a precise stimulation site. Again, because the stimulation apparatus 600 positions the electrodes 660 at least proximate to the pial surface 708, precise levels of stimulation with good pulse shape fidelity will be accurately transmitted to the stimulation site in the brain. It will be appreciated that transcranial therapies may not be able to apply stimulation to a precise stimulation site because the magnetic and electrical properties of the scalp and skull may vary from one patient to another such that an identical stimulation by the transcranial device may produce a different level of stimulation at the neurons in each patient. Moreover, the ability to focus the stimulation to a precise area is hindered by delivering the stimulation transcranially because the scalp, skull and dura all diffuse the energy from a transcranial device. Several embodiments of the stimulation apparatus 600 overcome this drawback because the electrodes 660 are positioned under the skull 700 such that the pulses generated by the stimulation apparatus 600 are not diffused by the scalp 702 and skull 700.
2. Integrated Pulse Systems for Implantable Stimulation Apparatus
The pulse system 630 shown in
Referring to
The pulse system 1200 can be housed within the stimulation apparatus 600 (not shown). In one embodiment, the pulse system 1200 includes an antenna 1260 and a pulse delivery system 1270. The antenna 1260 incorporates a diode (not shown) that rectifies the broadcast RF energy from the antenna 1242. The pulse delivery system 1270 can include a filter 1272 and a pulse former 1274 that forms electrical pulses which correspond to the RF energy broadcast from the antenna 1242. The pulse system 1200 is accordingly powered by the RF energy in the pulse signal from the external controller 1210 such that the pulse system 1200 does not need a separate power supply carried by the stimulation apparatus 600.
The pulse system 1300 can include a ferrite core 1360 and a coil 1362 wrapped around a portion of the ferrite core 1360. The pulse system 1310 can also include a pulse delivery system 1370 including a rectifier and a pulse former. In operation, the ferrite core 1360 and the coil 1362 convert the changes in the magnetic field generated by the magnetic coupler 1350 into electrical pulses that are sent to the pulse delivery system 1370. The electrodes 660 are coupled to the pulse delivery system 1370 so that electrical pulses corresponding to the electrical pulses generated by the pulse generator 1330 in the external controller 1310 are delivered to the stimulation site on the patient.
3. Electrode Configurations
The first electrode 1410 can be coupled to the positive terminal of a pulse generator 1430, and the second electrode 1420 can be coupled to the negative terminal of the pulse generator 1430. Referring to
Several embodiments of the stimulation apparatus described above with reference to
4. Implantable Stimulation Apparatus with Biasing Elements
Although several embodiments of the stimulation apparatus shown in
5. Implantable Stimulation Apparatus with External Pulse Systems
The stimulation apparatus 3100, however, does not have an internal pulse system carried by the portion of the device that is implanted in the skull 700 of the patient 500. The stimulation apparatus 3100 receives electrical pulses from an external pulse system 3130. The external pulse system 3130 can have an electrical connector 3132 with a plurality of contacts 3134 configured to engage the contacts within the receptacle 3120. The external pulse system 3130 can also have a power supply, controller, pulse generator, and pulse transmitter to generate the electrical pulses. In operation, the external pulse system 3130 sends electrical pulses to the stimulation apparatus 3100 via the connector 3132, the receptacle 3120, and the lead line 3124.
Referring to
6. Alternate Embodiments of Implantable Stimulation Apparatus
In one embodiment, the stimulation apparatus 3600 can receive electrical pulses from an external controller 3630. For example, the external controller 3630 can be electrically coupled to the stimulation apparatus 3600 by a lead line 3632 that passes through a hole 711 in the skull 700. In an alternative embodiment, the stimulation apparatus 3600 can include an integrated pulse system similar to the pulse systems described above with reference to
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
This application is a continuation-in-part of U.S. application Ser. No. 09/802,808, filed Mar. 8, 2001 now U.S. Pat. No. 7,010,351, which claims the benefit of U.S. Provisional Application No. 60/217,981, filed Jul. 13, 2000, which are both incorporated herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2721316 | Shaw | Oct 1955 | A |
| 3628193 | Collins | Dec 1971 | A |
| 3650276 | Burghele et al. | Mar 1972 | A |
| 4030509 | Heilman et al. | Jun 1977 | A |
| 4125116 | Fischell | Nov 1978 | A |
| 4140133 | Kastrubin et al. | Feb 1979 | A |
| 4214804 | Little | Jul 1980 | A |
| 4245645 | Picard et al. | Jan 1981 | A |
| 4328813 | Ray | May 1982 | A |
| 4431000 | Butler et al. | Feb 1984 | A |
| 4474186 | Ledley et al. | Oct 1984 | A |
| 4542752 | DeHaan et al. | Sep 1985 | A |
| 4590946 | Loeb | May 1986 | A |
| 4607639 | Tanagho et al. | Aug 1986 | A |
| 4646744 | Capel | Mar 1987 | A |
| 4844075 | Liss et al. | Jul 1989 | A |
| 4865048 | Eckerson | Sep 1989 | A |
| 4969468 | Byers et al. | Nov 1990 | A |
| 5002053 | Garcia-Rill et al. | Mar 1991 | A |
| 5024226 | Tan | Jun 1991 | A |
| 5031618 | Mullett | Jul 1991 | A |
| 5054906 | Lyons | Oct 1991 | A |
| 5063932 | Dahl et al. | Nov 1991 | A |
| 5092835 | Schurig et al. | Mar 1992 | A |
| 5121754 | Mullett | Jun 1992 | A |
| 5143089 | Alt | Sep 1992 | A |
| 5169384 | Bosniak et al. | Dec 1992 | A |
| 5184620 | Cudahy et al. | Feb 1993 | A |
| 5215086 | Terry, Jr. et al. | Jun 1993 | A |
| 5224491 | Mehra | Jul 1993 | A |
| 5255678 | Deslauriers et al. | Oct 1993 | A |
| 5263967 | Lyons | Nov 1993 | A |
| 5271417 | Swanson et al. | Dec 1993 | A |
| 5282468 | Klepinski | Feb 1994 | A |
| 5299569 | Wernicke et al. | Apr 1994 | A |
| 5304206 | Baker, Jr. et al. | Apr 1994 | A |
| 5314458 | Najafi et al. | May 1994 | A |
| 5358513 | Powell, III et al. | Oct 1994 | A |
| 5370672 | Fowler et al. | Dec 1994 | A |
| 5405375 | Ayers et al. | Apr 1995 | A |
| 5406957 | Tansey | Apr 1995 | A |
| 5411540 | Edell et al. | May 1995 | A |
| 5417719 | Hull et al. | May 1995 | A |
| 5423864 | Ljungstroem | Jun 1995 | A |
| 5464446 | Dreessen et al. | Nov 1995 | A |
| 5520190 | Benedict et al. | May 1996 | A |
| 5522864 | Wallace et al. | Jun 1996 | A |
| 5537512 | Hsia et al. | Jul 1996 | A |
| 5540736 | Haimovish et al. | Jul 1996 | A |
| 5549655 | Erickson | Aug 1996 | A |
| 5562708 | Combs et al. | Oct 1996 | A |
| 5575813 | Edell | Nov 1996 | A |
| 5591216 | Testerman et al. | Jan 1997 | A |
| 5593432 | Crowther et al. | Jan 1997 | A |
| 5601611 | Fayram et al. | Feb 1997 | A |
| 5628317 | Starkebaum et al. | May 1997 | A |
| 5674251 | Combs et al. | Oct 1997 | A |
| 5676655 | McCulloch et al. | Oct 1997 | A |
| 5683422 | Rise | Nov 1997 | A |
| 5702429 | King | Dec 1997 | A |
| 5711316 | Elsberry et al. | Jan 1998 | A |
| 5713922 | King | Feb 1998 | A |
| 5713923 | Ward et al. | Feb 1998 | A |
| 5716377 | Rise et al. | Feb 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5735814 | Elsberry et al. | Apr 1998 | A |
| 5752979 | Benabid | May 1998 | A |
| 5772591 | Cram | Jun 1998 | A |
| 5782798 | Rise | Jul 1998 | A |
| 5782873 | Collins | Jul 1998 | A |
| 5792186 | Rise | Aug 1998 | A |
| 5797970 | Pouvreau | Aug 1998 | A |
| 5814014 | Elsberry et al. | Sep 1998 | A |
| 5814092 | King | Sep 1998 | A |
| 5824021 | Rise | Oct 1998 | A |
| 5824030 | Yang et al. | Oct 1998 | A |
| 5832932 | Elsberry et al. | Nov 1998 | A |
| 5833709 | Rise et al. | Nov 1998 | A |
| 5843148 | Gijsbers et al. | Dec 1998 | A |
| 5843150 | Dreessen et al. | Dec 1998 | A |
| 5865842 | Knuth et al. | Feb 1999 | A |
| 5885976 | Sandyk | Mar 1999 | A |
| 5886769 | Zolten | Mar 1999 | A |
| 5893883 | Torgerson et al. | Apr 1999 | A |
| 5904916 | Hirsch | May 1999 | A |
| 5913882 | King | Jun 1999 | A |
| 5925070 | King et al. | Jul 1999 | A |
| 5938688 | Schiff | Aug 1999 | A |
| 5938689 | Fischell et al. | Aug 1999 | A |
| 5941906 | Barreras, Sr. et al. | Aug 1999 | A |
| 5964794 | Bolz et al. | Oct 1999 | A |
| 5975085 | Rise | Nov 1999 | A |
| 5978702 | Ward et al. | Nov 1999 | A |
| 5983140 | Smith et al. | Nov 1999 | A |
| 6006124 | Fischell et al. | Dec 1999 | A |
| 6011996 | Gielen et al. | Jan 2000 | A |
| 6016449 | Fischell et al. | Jan 2000 | A |
| 6018682 | Rise | Jan 2000 | A |
| 6021352 | Christopherson et al. | Feb 2000 | A |
| 6026326 | Bardy | Feb 2000 | A |
| 6035236 | Jarding et al. | Mar 2000 | A |
| 6040180 | Johe | Mar 2000 | A |
| 6042579 | Elsberry et al. | Mar 2000 | A |
| 6052624 | Mann | Apr 2000 | A |
| 6055456 | Gerber | Apr 2000 | A |
| 6057846 | Sever, Jr. | May 2000 | A |
| 6058331 | King | May 2000 | A |
| 6060048 | Cherksey | May 2000 | A |
| 6061593 | Fischell et al. | May 2000 | A |
| 6066163 | John | May 2000 | A |
| 6104956 | Naritoku et al. | Aug 2000 | A |
| 6104960 | Duysens et al. | Aug 2000 | A |
| 6122548 | Starkebaum et al. | Sep 2000 | A |
| 6126657 | Edwards et al. | Oct 2000 | A |
| 6128537 | Rise | Oct 2000 | A |
| 6128538 | Fischell et al. | Oct 2000 | A |
| 6134474 | Fischell et al. | Oct 2000 | A |
| 6152143 | Edwards | Nov 2000 | A |
| 6161044 | Silverstone | Dec 2000 | A |
| 6161045 | Fischell et al. | Dec 2000 | A |
| 6198958 | Ives et al. | Mar 2001 | B1 |
| 6205360 | Carter et al. | Mar 2001 | B1 |
| 6210417 | Baudino et al. | Apr 2001 | B1 |
| 6221908 | Kilgard et al. | Apr 2001 | B1 |
| 6230049 | Fischell et al. | May 2001 | B1 |
| 6236892 | Feler | May 2001 | B1 |
| 6280462 | Hauser et al. | Aug 2001 | B1 |
| 6301493 | Marro et al. | Oct 2001 | B1 |
| 6339725 | Naritoku et al. | Jan 2002 | B1 |
| 6353754 | Fischell et al. | Mar 2002 | B1 |
| 6354299 | Fischell et al. | Mar 2002 | B1 |
| 6356792 | Errico | Mar 2002 | B1 |
| 6360122 | Fischell et al. | Mar 2002 | B1 |
| 6366813 | DiLorenzo | Apr 2002 | B1 |
| 6375666 | Mische | Apr 2002 | B1 |
| 6405079 | Ansarinia | Jun 2002 | B1 |
| 6418344 | Rezai et al. | Jul 2002 | B1 |
| 6427086 | Fischell et al. | Jul 2002 | B1 |
| 6459936 | Fischell et al. | Oct 2002 | B1 |
| 6463328 | John | Oct 2002 | B1 |
| 6464356 | Sabel | Oct 2002 | B1 |
| 6466822 | Pless | Oct 2002 | B1 |
| 6473639 | Fischell et al. | Oct 2002 | B1 |
| 6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
| 6484059 | Gielen | Nov 2002 | B1 |
| 6487450 | Chen | Nov 2002 | B1 |
| 6499488 | Hunter et al. | Dec 2002 | B1 |
| 6505075 | Weiner | Jan 2003 | B1 |
| 6507755 | Gozani et al. | Jan 2003 | B1 |
| 6597954 | Pless et al. | Jul 2003 | B1 |
| 6615065 | Barrett et al. | Sep 2003 | B1 |
| 6622048 | Mann | Sep 2003 | B1 |
| 6633780 | Berger | Oct 2003 | B1 |
| 6665562 | Gluckman et al. | Dec 2003 | B1 |
| 6687525 | Llinas | Feb 2004 | B1 |
| 6690974 | Archer et al. | Feb 2004 | B1 |
| 6725094 | Saberski | Apr 2004 | B1 |
| 6764498 | Mische | Jul 2004 | B1 |
| 6782292 | Whitehurst | Aug 2004 | B1 |
| 6795737 | Gielen et al. | Sep 2004 | B1 |
| 6810286 | Donovan et al. | Oct 2004 | B1 |
| 6839594 | Cohen et al. | Jan 2005 | B1 |
| 6873872 | Gluckman et al. | Mar 2005 | B1 |
| 6892097 | Holsheimer | May 2005 | B1 |
| 6895280 | Meadows et al. | May 2005 | B1 |
| 6907296 | Doan et al. | Jun 2005 | B1 |
| 6934580 | Osorio et al. | Aug 2005 | B1 |
| 6944497 | Stypulkowski | Sep 2005 | B1 |
| 6959215 | Gliner et al. | Oct 2005 | B1 |
| 6990377 | Gliner et al. | Jan 2006 | B1 |
| 7010351 | Firlik et al. | Mar 2006 | B1 |
| 7024247 | Gliner et al. | Apr 2006 | B1 |
| 20020028072 | Kashiyama | Mar 2002 | A1 |
| 20020077670 | Archer et al. | Jun 2002 | A1 |
| 20020091419 | Firlik et al. | Jul 2002 | A1 |
| 20020099412 | Fischell et al. | Jul 2002 | A1 |
| 20020169485 | Pless et al. | Nov 2002 | A1 |
| 20030074032 | Gliner | Apr 2003 | A1 |
| 20030078633 | Firlik et al. | Apr 2003 | A1 |
| 20030088274 | Gliner et al. | May 2003 | A1 |
| 20030097161 | Firlik et al. | May 2003 | A1 |
| 20030125772 | Olson et al. | Jul 2003 | A1 |
| 20030125786 | Gliner et al. | Jul 2003 | A1 |
| 20030130706 | Sheffield et al. | Jul 2003 | A1 |
| 20030149457 | Tcheng et al. | Aug 2003 | A1 |
| 20030176901 | May | Sep 2003 | A1 |
| 20030187490 | Gliner | Oct 2003 | A1 |
| 20030187491 | Greenberg et al. | Oct 2003 | A1 |
| 20040073270 | Firlik et al. | Apr 2004 | A1 |
| 20040082847 | McDermott | Apr 2004 | A1 |
| 20040092809 | DeCharms | May 2004 | A1 |
| 20040102828 | Lowry et al. | May 2004 | A1 |
| 20040111127 | Gliner et al. | Jun 2004 | A1 |
| 20040138550 | Hartlep et al. | Jul 2004 | A1 |
| 20040176831 | Gliner et al. | Sep 2004 | A1 |
| 20040181263 | Balzer et al. | Sep 2004 | A1 |
| 20040215287 | Swoyer et al. | Oct 2004 | A1 |
| 20040236388 | Gielen et al. | Nov 2004 | A1 |
| 20040243205 | Keravel et al. | Dec 2004 | A1 |
| 20040249422 | Gliner et al. | Dec 2004 | A1 |
| 20050004620 | Singhal et al. | Jan 2005 | A1 |
| 20050015129 | Mische | Jan 2005 | A1 |
| 20050021105 | Firlik et al. | Jan 2005 | A1 |
| 20050021106 | Firlik et al. | Jan 2005 | A1 |
| 20050021107 | Firlik et al. | Jan 2005 | A1 |
| 20050021118 | Genau et al. | Jan 2005 | A1 |
| 20050033378 | Sheffield et al. | Feb 2005 | A1 |
| 20050070971 | Fowler et al. | Mar 2005 | A1 |
| 20050075679 | Gliner et al. | Apr 2005 | A1 |
| 20050075680 | Lowry et al. | Apr 2005 | A1 |
| 20050096701 | Donovan et al. | May 2005 | A1 |
| 20050113882 | Cameron et al. | May 2005 | A1 |
| 20050119712 | Shafer | Jun 2005 | A1 |
| 20050154425 | Boveja et al. | Jul 2005 | A1 |
| 20050154426 | Boveja et al. | Jul 2005 | A1 |
| 20060015153 | Gliner et al. | Jan 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| 19750043 | May 1999 | DE |
| 0319844 | Jun 1989 | EP |
| 0 998 958 | Oct 2000 | EP |
| 1145736 | Oct 2001 | EP |
| 1180056 | Nov 2003 | EP |
| WO8707511 | Dec 1987 | WO |
| WO 9407564 | Apr 1994 | WO |
| WO 9521591 | Aug 1995 | WO |
| WO 9806342 | Feb 1998 | WO |
| WO 0197906 | Dec 2001 | WO |
| WO0209811 | Feb 2002 | WO |
| WO0236003 | May 2002 | WO |
| WO0238031 | May 2002 | WO |
| WO0238217 | May 2002 | WO |
| WO-03082402 | Mar 2003 | WO |
| WO-03043690 | May 2003 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20020091419 A1 | Jul 2002 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60217981 | Jul 2000 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09802808 | Mar 2001 | US |
| Child | 10072700 | US |
